The current "instruments and tools used to assess the value of cancer medicines may be too “blunt” to capture the true potential of future therapies and technologies to treat small patient populations, says a discussion paper released by Rare Cancers Australia. …
Latest Video
New Stories
-
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News -
Australian company secures Mitsubishi partnership to bring BioPQQ to market
August 26, 2026 - - Latest News -
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech -
Argent BioPharma takes CannEpil into US veterinary regulatory process
August 26, 2026 - - Latest News -
Entropy takes TRP-8803 to the US in head-to-head depression trial
August 26, 2026 - -
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech